Search for Clinical Trial Results

Sponsored By

Choroidal Neovascularization - 25 Studies Found

Status Study
Completed Study Name: Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Condition: Choroidal Neovascularization
Date: 2006-08-09
Interventions:
  • Drug: Ranibizumab 0.3 mg/0.05

Completed Study Name: Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
Condition: Choroidal Neovascularisation
Date: 2009-12-21
Interventions: Drug: ranibizumab 0.5mg
Recruiting Study Name: Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
Condition: Choroidal Neovascularization
Date: 2014-10-06
Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) Administration by intravitreal injection
Recruiting Study Name: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
Condition: Choroidal Neovascularization
Date: 2016-08-21
Interventions: Drug: 0.5mg intravitreal ranibizumab Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerla
Completed Study Name: Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
Condition: Choroidal Neovascularization
Date: 2007-08-01
Interventions: Drug: Intravitreal injection ranibizumab Monthly intravitreal injection of 0.5mg ranibizumab in one eye
Recruiting Study Name: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
Condition: Idiopathic Choroidal Neovascularization
Date: 2016-07-27
Interventions: Drug: conbercept 0.05ml conbercept Other Name: conbe
Recruiting Study Name: Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
Condition: Type 3 Choroidal Neovascularization
Date: 2014-12-10
Interventions: Drug: Aflibercept
Recruiting Study Name: TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration
Condition: Choroidal Neovascularization
Date: 2005-11-29
Interventions: Procedure: Photodynamic therapy versus Transpupillary thermotherapy
Completed Study Name: Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
Condition: Myopic Choroidal Neovascularization
Date: 2008-11-24
Interventions: Drug: Injection Intravitreal injection of 1.25 mg bevacizumab
Withdrawn Study Name: Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Condition: Choroidal Neovascularization
Date: 2006-11-22
Interventions: Drug: Imatinib Mesylate /Ranibizumab
Next >>>